StocktoriaIN8BIO, INC. INAB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
-7.15
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Operating cash flow | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M |
| Shareholders' equity | $27.6M | $14.5M | $24.9M | $22.7M | -$38.2M |
| Ratios | |||||
| Return on assets | -60.2% | -145.3% | -89.0% | -86.3% | -34.7% |
| Return on equity | -70.5% | -210.2% | -120.3% | -125.5% | 38.4% |
| Current ratio | 8.82 | 4.08 | 4.57 | 3.82 | 17.28 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.15 (distress)
- Working capital / assets 0.766
- Retained earnings / assets -4.371
- EBIT / assets -0.602
- Equity / liabilities 5.834
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001740279 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.